Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380022 | 0.82 | KIF11 (1.00) | KIF11CA1CA2 | |
| SCHEMBL4661134 | 0.79 | KIF11 (1.00) | KIF11CA1CA2MEN1KMT2A | |
| SCHEMBL5531754 | 0.79 | KIF11 (1.00) | KIF11CA1CA2 | |
| SCHEMBL5444711 | 0.79 | KIF11 (0.69) | KIF11CA1CA2MEN1KMT2A | |
| SCHEMBL15448493 | 0.78 | ALDH1A1 (0.55) | CA1CA2MEN1KMT2APTPN11 | |
| SCHEMBL5529266 | 0.78 | KIF11 (1.00) | KIF11CA1CA2MEN1KMT2A | |
| SCHEMBL13656086 | 0.76 | KIF11 (0.89) | KIF11CA1CA2MEN1KMT2A | |
| SCHEMBL5428301 | 0.75 | KIF11 (1.00) | KIF11CA1CA2 | |
| SCHEMBL26422694 | 0.74 | CA1 (0.68) | KIF11CA1CA2MEN1KMT2A | |
| SCHEMBL3364543 | 0.74 | CA1 (0.68) | KIF11CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | claimed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | claimed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | claimed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885CA1 2205/4885CA2 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.